One Protein Fights Inflammaging and Made Aging Mice Stronger and Healthier
Scientists boosted a protein that dampens chronic inflammation, and older mice grew stronger, more energetic, and had healthier bones.
Summary
Researchers at the University at Buffalo identified a protein called tristetraprolin (TTP) that helps control the low-grade chronic inflammation associated with aging, known as inflammaging. As people age, TTP levels naturally decline, allowing inflammatory signals to accumulate and damage tissues. In a six-year NIH-funded study, scientists genetically modified elderly mice to maintain stable TTP levels. Those mice showed measurable improvements in strength, energy, and bone health compared to untreated aging mice. The findings, published in Aging and Disease, suggest that restoring TTP activity could one day become a therapeutic strategy to reduce frailty, preserve independence, and extend healthspan in older adults.
Detailed Summary
Chronic low-grade inflammation — dubbed inflammaging — is one of the most damaging and pervasive processes driving age-related decline. It weakens immunity, erodes bone density, depletes energy, and accelerates frailty. Despite its central role in aging, few targeted therapies exist to address it at a molecular level. New research from the University at Buffalo may offer a promising path forward.
Scientists focused on a protein called tristetraprolin (TTP), an RNA-binding protein that degrades pro-inflammatory messenger molecules before they can accumulate and cause harm. TTP essentially acts as a molecular brake on inflammation. The problem is that TTP levels naturally fall as we age, particularly in immune cells, leaving inflammation increasingly unchecked.
To test whether restoring TTP could reverse age-related decline, the research team genetically engineered elderly mice to maintain stable, elevated TTP levels. The results were striking. Compared to untreated aging mice, the TTP-boosted group demonstrated greater muscular strength, higher energy levels, and significantly healthier bone structure — all key markers of healthspan and reduced frailty.
The study, supported by a $2.1 million NIH grant and conducted over six years, was published in the January 2026 issue of Aging and Disease. Senior researcher Keith Kirkwood emphasized that understanding the link between inflammaging, immune system changes, bone health, and frailty is essential for building effective interventions that help aging populations stay independent longer.
Caveats remain significant. This research was conducted entirely in mice using genetic modification, not a drug or supplement, meaning human translation is still years away. TTP cannot currently be boosted through lifestyle or over-the-counter means. Nevertheless, the findings validate inflammaging as a high-value therapeutic target and suggest that controlling inflammatory RNA signals could become a cornerstone of future anti-frailty medicine.
Key Findings
- Boosting TTP protein in aging mice improved strength, energy, and bone health significantly
- TTP acts as a molecular brake on inflammaging by degrading pro-inflammatory RNA signals
- TTP levels naturally decline with age in immune cells, allowing chronic inflammation to spread
- Genetically stabilizing TTP in elderly mice reduced markers of frailty over a six-year study
- Findings support inflammaging as a viable therapeutic target for human healthspan interventions
Methodology
This is a news summary of peer-reviewed research published in Aging and Disease (January 2026) from the University at Buffalo, funded by a $2.1 million NIH grant. The study used genetically modified mouse models over six years, representing rigorous preclinical evidence. Source credibility is high; findings have not yet been replicated in human trials.
Study Limitations
All findings are from genetically modified mouse models and have not been tested in humans. TTP was elevated via genetic engineering, not a drug or supplement, so no direct consumer action is currently possible. Human translation timelines and safety profiles remain entirely unknown and should be verified with the primary paper in Aging and Disease.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.